What Кальцинова Treats: Main Uses and Benefits

The Кальцинова preparation is commonly used across therapeutic domains where nutritional support and micronutrient correction are needed. As a combination product, it is primarily used for its core components: Calcium and Cholecalciferol (Vitamin D3). Vitamin D3 is utilized alongside calcium to help prevent and treat bone diseases such as rickets and osteomalacia.

Primary Therapeutic Focus and Benefits

This preparation is commonly used to support functional stability and the development of strong bones in pediatric and adolescent patients. It helps address the nutritional causes of conditions such as Nutritional Rickets, Osteomalacia, and states of systemic mineral imbalance. The supplement is applied in addressing symptoms related to increased neurological or muscular activity, which may include muscle cramps and spasms associated with low calcium status. This provides support that helps ease the overall symptom burden and contributes to the development of strong bones.

The product is considered relevant for patient groups when dietary intake is insufficient or requirements are elevated, such as during periods of rapid growth. It assists with maintaining functional stability and supporting general well-being in these contexts.

“This nutritional support is important for patients, especially children, whose systemic imbalance may benefit from supportive symptomatic assistance.”

---

Quick Fact: Relief for Nutritional Deficits

Property	Description
Primary Domain	Musculoskeletal Support and Deficiency Management
Symptom Focus	Muscle cramps and spasms (associated with mineral status), skeletal weakness
Typical Context	Growth spurts, inadequate dietary intake (high-risk scenarios)
Patient Benefit	Supports functional stability and eases overall symptom burden

Regulatory References

1. MedlinePlus overview of Cholecalciferol

The eligibility for Кальцинова, a multivitamin and multimineral supplement, is governed by official regulatory documentation focusing on pre-existing metabolic conditions, organ function, and specific life stages.

Populations for Whom Use is Prohibited (Contraindicated)

Use of this preparation is strictly contraindicated in patients with conditions that result in excessive levels of the active ingredients, specifically Hypercalcemia (high blood calcium) or Hypervitaminosis D (high Vitamin D levels). It must also not be used by individuals with Hypercalciuria, Nephrolithiasis (kidney stones), or severe Renal Impairment.

Conditional or Restricted Eligibility

Category	Official Regulatory Status
Age-Related Use	Children under 12 years of age are generally not recommended for certain high-strength combination formulations; eligibility is tied to the specific product strength.
Pregnancy/Lactation	Conditional: Permitted under medical guidance, but doses of Vitamin D that exceed the recommended dietary allowance (RDA) must be avoided during this time.
Organ Function	Patients with non-severe Renal Impairment or conditions like Sarcoidosis require caution and regular monitoring of calcium levels due to increased risk of mineral imbalance.

The interaction profile for Кальцинова is defined by its core components—Calcium, Cholecalciferol (Vitamin D3), and Folic Acid—and is structured around regulatory classifications including chelation, metabolic inactivation, and additive pharmacodynamic risk.

Pharmacokinetic and Timing Restrictions

The Calcium content can cause a pharmacokinetic interaction by chelation, leading to a documented reduction in the systemic exposure of co-administered medicines. This effect is specifically noted for Tetracycline and Fluoroquinolone Antibiotics, and Oral Bisphosphonates. Regulatory labeling mandates that administration must be separated by specific time intervals, often ranging from two to six hours, to mitigate this reduced efficacy.

Additive Risk and Metabolic Interactions

Pharmacodynamic interactions establish an additive risk of hypercalcemia. This is increased when co-administered with Thiazide Diuretics, and the elevated calcium status can increase the risk of Digitalis toxicity with Cardiac Glycosides (e.g., Digoxin). The effectiveness of the Vitamin D3 component may be officially reduced by metabolic inactivation when co-administered with Anticonvulsants (e.g., Phenytoin) or Glucocorticoids.

Other Restrictions and Considerations

The product’s Folic Acid content carries a specific restriction: high doses (>1 mg/day) are officially cautioned against in patients with undiagnosed anemia to prevent the masking of symptoms. The absorption of Vitamin D3 is also reduced by substances such as Mineral Oil. Additionally, patients with renal impairment are documented as having an increased susceptibility to interaction-related hypercalcemia.

Кальцинова is an orally administered combination agent which elevates circulating concentrations of calcium and the vitamin D metabolite, calcitriol. The calcium component increases the mineral's systemic concentration, acting as a substrate for numerous physiological processes, including bone mineralization, muscle contraction, and transmembrane ion flux across excitable cells. The calcitriol component, the active hormonal form of vitamin D, acts as a nuclear receptor agonist targeting the Vitamin D Receptor (VDR), which is expressed in target tissues like the intestine and kidney.

Upon binding, the calcitriol-VDR complex translocates to the cell nucleus and heterodimerizes with the Retinoid X Receptor (RXR). This complex binds to Vitamin D Response Elements (VDREs) in the promoter region of target genes. This genomic signaling pathway modulates gene transcription, leading to increased expression of proteins involved in calcium and phosphate transport, such as calbindin-D28k. Intracellularly, this enhances the active absorption of calcium and phosphate across the intestinal mucosa. At the system level, this coordinated action increases the plasma concentration of both calcium and phosphate, contributing to the maintenance of mineral homeostasis.

The administration of Кальцинова, a combination product containing Calcium Carbonate and Cholecalciferol (Vitamin D3), is performed according to specific parameters for proper usage.

Administration Principles

The approved route of administration for this supplement is Oral. The tablet is designed to be chewed or sucked and must not be swallowed whole to ensure correct utilization. The administration pattern is generally defined as long-term supplementation for deficiency correction.

Feature	Usage Guidelines
Dosing Schedule	Dosing is based on the patient's age and need, often requiring a total daily intake of elemental Calcium in the range of 1000 mg to 1200 mg, typically delivered as one or two tablets daily depending on the specific product strength.
Frequency	The daily dose is scheduled for administration either once daily or in divided doses to optimize absorption and reach the necessary total daily intake.
Age-Group Rules	Pediatric dosing is explicitly defined in product documentation; for example, specific formulations may be administered once to twice per day for children within specified age groups.

Procedural Requirements

To ensure proper administration, special procedural conditions must be observed. While the supplement may be taken with or without food, co-administration with certain other medications, such as tetracycline or quinolone antibiotics, requires a separation interval of two to four hours. This timing constraint is necessary to prevent the Calcium component from interfering with the absorption of the other medications. Should a dose be missed, the standard procedure is to skip the missed dose if it is near the time for the next scheduled dose, and then resume the regular pattern without doubling the dose.

Research evidence / Overview of Studies for Кальцинова

Evidence for Use in Skeletal Disorders Related to Nutritional Deficiency

Research examined the components of this preparation and outcomes related to conditions like nutritional rickets and osteomalacia. Research has relied on Randomized Controlled Trials (RCTs) and Systematic Reviews involving infants, children, and adolescents. The study outcomes examined included the evaluation of radiographic changes and shifts in biochemical markers, such as serum 25-hydroxyvitamin D (25( OH) D). Short-term trials, often lasting 12 to 24 weeks, studies monitored measurements of these parameters. However, comparative evidence remains limited from large-scale studies directly examining the combination against single agents or other treatments over long timeframes.

Evidence for Correcting General Vitamin D and Calcium Deficits

The combination was evaluated in a broader research context where research examined outcomes related to overall nutritional deficiency. These studies explored how supplementation affects serum 25( OH) D concentration and Bone Mineral Density (BMD). The findings related to biomarker shifts showed patterns associated with changes in 25( OH) D levels in individuals who were previously deficient. However, the findings were mixed when evaluating the relationship between BMD measurements and supplementation in healthy, non-deficient children. The results apply only to the populations studied, and long-term data often draw from adult and older adult populations.

Research Gaps, Long-Term Outcomes, and Special Populations

The Folic Acid component was observed in research that contributes to the broader evidence landscape related to folate status, with the highest level of evidence focused on pregnant women. Evidence concerning its influence on general growth or haematological outcomes in the primary pediatric and adolescent population is sparse, and sample sizes were modest. A key limitation is that follow-up durations were limited in many comparative trials, meaning that long-term effects are not fully established regarding the duration of observed biochemical marker changes after use is discontinued. Direct comparative evidence for the full combination in groups like those with comorbid conditions is limited, and data for certain groups remain insufficient to fully characterize the research profile. This means that the certainty remains low for some findings, and findings describe group patterns, not personal outcomes.

Common questions about Кальцинова (FAQ)

Q: Is Кальцинова the same as other calcium supplements?

A: Official product information describes Кальцинова as a combination product. This means it contains not only a form of calcium but also other active components, typically Cholecalciferol (Vitamin D3) and/or other minerals. This composition is a key distinction from single-ingredient supplements that contain only calcium.

Q: What should I do if I accidentally miss a use of Кальцинова?

A: Official instructions generally describe that the standard procedure is to resume the product at the next scheduled time. Regulatory guidance advises against attempting to double the dose to make up for the one that was missed.

Q: Can I take Кальцинова if I am on other daily supplements?

A: Regulatory documents describe interactions with certain medications and caution that using other products containing high doses of calcium, Vitamin D, or Folic Acid increases the risk of side effects like hypercalcemia (high blood calcium levels). Official information advises that checking the content of all supplements is important to avoid exceeding established daily limits.

Q: What is the difference between Кальцинова and a general multivitamin?

A: Кальцинова is officially classified as a Vitamin and mineral combination supplement. Regulatory descriptions focus on its primary role as a concentrated source of Calcium and Cholecalciferol (Vitamin D3) for deficiency correction. This formulation differs from general multivitamins, which are typically formulated to supply a wider, less concentrated range of nutrients for daily maintenance.

Q: Is Кальцинова safe for long-term use?

A: Regulatory texts establish constraints on use, noting that the risk of hypercalcaemia (high blood calcium) and organ calcification is officially associated with long-term or excessive use. Caution is documented in official warnings regarding the duration and quantity of administration.

Q: Can children or teenagers use Кальцинова?

A: Regulatory documents confirm that pediatric dosing is explicitly defined for use in both children and adolescents. However, it is noted that specific high-strength formulations may have restrictions, such as not being recommended for children under a certain age.

Q: Why does the packaging of Кальцинова mention vitamin D?

A: Official information confirms that Cholecalciferol (Vitamin D3) is included because it plays a critical role in the body's mineral balance. Vitamin D is necessary for the body to absorb and utilize the calcium component efficiently, which directly supports the maintenance of mineral homeostasis.

Q: Is Кальцинова effective for preventing fractures?

A: Studies have examined the components of this preparation and outcomes related to certain skeletal conditions, such as osteomalacia and rickets. However, regulatory summaries indicate that comparative evidence remains limited from large-scale studies directly examining the full combination over long periods.

Q: Does Кальцинова require any special monitoring by a doctor?

A: Regulatory guidance states that patients with certain conditions, such as non-severe renal impairment or sarcoidosis, require caution. For these individuals, regular monitoring of calcium levels may be required due to an increased risk of mineral imbalance.

Q: How is the safety of Кальцинова monitored after it is available to the public?

A: The safety of marketed products is actively and systematically monitored through official regulatory processes called pharmacovigilance and post-market surveillance. These frameworks collect and analyze reports of adverse events and new information that emerges from real-world use.

Q: Can Кальцинова affect results of blood tests?

A: The adverse reaction profile includes the possibility of causing Hypercalcemia (high blood calcium levels) and Hypercalciuria (high urine calcium levels). These documented biochemical changes may be observed in relevant blood and urine tests ordered by a healthcare professional.

Q: Is Кальцинова considered a 'drug' or a 'supplement'?

A: Official classification defines the preparation as a Vitamin and mineral combination supplement. It belongs to the pharmacological class of Oral nutritional supplements, formulated to supply a synergistic complex of multivitamins and minerals to address nutritional deficits.

Q: What is the importance of zinc in the Кальцинова formulation?

A: Official documentation describes the preparation as a multimineral complex. Research indicates that zinc is an essential cofactor for Vitamin D, as the functional activity of Vitamin D-dependent genes is supported by its presence.

Q: Are there different versions or strengths of Кальцинова available?

A: Regulatory documents refer to varying product strengths and specific formulations with differing calcium and Vitamin D contents. This variation necessitates different dosing schedules, such as 'one or two tablets daily,' indicating that multiple regulated versions of the product or similar generics exist.

Q: Is it true that Кальцинова is often used in combination with certain diets?

A: The general purpose of the preparation is officially described as dietary supplementation. It is intended to prevent or correct established states of nutritional deficiency that occur when dietary intake is insufficient, explicitly linking its use to complementing or correcting deficits in a user's regular diet.

Storage and Protection Requirements

Official regulatory labeling dictates that Кальцинова must be stored at a temperature not exceeding 25°C to maintain the stability of the multivitamin and multimineral components. The preparation requires continuous protection from light and moisture and must be kept in its original packaging until the moment of use. Adherence to these conditions is essential for maintaining the product's 2-year labeled shelf life. It is a mandatory requirement that the medicine be stored out of the sight and reach of children to prevent accidental ingestion.

Official Disposal Instructions

No special handling requirements for disposal are specified in the labeling. Any unused or expired product must be discarded in accordance with local regulations for pharmaceutical waste and must not be thrown into household waste or flushed down the toilet.